Search

Your search keyword '"Grenier, Julien"' showing total 265 results

Search Constraints

Start Over You searched for: Author "Grenier, Julien" Remove constraint Author: "Grenier, Julien"
265 results on '"Grenier, Julien"'

Search Results

2. Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial

3. Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AML

4. Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program

8. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

9. Clinical utility of ctDNA as a tool to detect triple-negative breast cancer relapses: The CUPCAKE trial.

10. Phase Ib INEOV neoadjuvant trial of durvalumab +/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): Survival outcomes and immune correlates.

11. Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study.

12. Trastuzumab deruxtecan in previously treated HER2‐positive metastatic or unresectable breast cancer: Real‐life data from the temporary use authorization program in France

16. Circadian Expression of Migratory Factors Establishes Lineage-Specific Signatures that Guide the Homing of Leukocyte Subsets to Tissues

19. Supplementary Figure S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

20. Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

21. Data from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

22. Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

25. GPR56/ADGRG1 is associated with response to antidepressant treatment

26. Antidepressive effects of targeting ELK-1 signal transduction

27. Dépistage du cancer du sein : en route vers le futur

28. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

30. Abstract P4-07-54: Health related quality of life of patients treated with bevacizumab and paclitaxel as first-line treatment for HER2 negative metastatic breast cancer: impact of clinical factors

31. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial

32. Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

33. Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer

35. Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program

37. Lithium enhances remyelination of peripheral nerves

38. A nomogram to predict progression-free survival benefit with maintenance olaparib and bevacizumab following response to first line chemotherapy in advanced ovarian cancer (305)

40. RNA-Seq is not required to determine stable reference genes for qPCR normalization

41. Abstract PD9-08: Prognostic value of EndoPredict test in patients screened for UNIRAD, a UCBG randomized, double blind, phase III international trial evaluating the addition of everolimus (EVE) to adjuvant hormone therapy (HT) in women with high risk HR+, HER2- early breast cancer (eBC)

43. Immune-Related Genetic Overlap Between Regional Gray Matter Reductions and Psychiatric Symptoms in Adolescents, and Gene-Set Validation in a Translational Model

44. Author Reply to Peer Reviews of RNA-Seq is not required to determine stable reference genes for qPCR normalization

46. Alpelisib and fulvestrant efficacy in HR-positive HER2-negative PIK3CA -mutant advanced breast cancer: Data from the French early access program

48. RNA-Seq is not required to determine stable reference genes for qPCR normalization

Catalog

Books, media, physical & digital resources